| Developing cohort | Validation cohort | P |
---|---|---|---|
Total | 629 | 553 | Â |
Age, ≤ 65/>65 (years) | 308/321 | 267/286 | 0.814 |
Sex, male/female | 387/242 | 337/216 | 0.837 |
Tumor location, head/neck/uncinate, body/tail | 388/241 | 355/198 | 0.373 |
CA19-9, < 37/≥37 U/mL | 177/452 | 127/426 | 0.563 |
T stage, T1/2/3 | 129/338/162 | 114/307/132 | 0.743 |
N stage, N0/1/2 | 182/294/153 | 203/203/147 | 0.612 |
TNM stage, I/II/III | 144/332/153 | 159/247/147 | 0.635 |
PNI, with/without | 599/30 | 515/38 | 0.121 |
LVI, with/without | 90/539 | 98/455 | 0.109 |
R status, R0/R1 | 503/126 | 411/142 | 0.597 |
Grade, G1/2/3/4 | 72/426/123/8 | 65/374/105/9 | 0.954 |
Grade, G1-2/3–4 | 496/133 | 437/116 | 0.944 |
Ki-67, < 40%/≥40% | 230/399 | 157/396 | 0.002 |
G-Ki67, I/II/III | 200/296/133 | 128/309/116 | 0.002 |
Adjuvant therapy, with/without | 356/273 | 329/224 | 0.314 |